News Image

MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities

Provided By GlobeNewswire

Last update: Aug 14, 2025

ROCKVILLE, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2025, and highlighted recent corporate progress.

Read more at globenewswire.com

MACROGENICS INC

NASDAQ:MGNX (10/3/2025, 8:00:01 PM)

After market: 1.78 0 (0%)

1.78

+0.07 (+4.09%)



Find more stocks in the Stock Screener

MGNX Latest News and Analysis

Follow ChartMill for more